Written by a leading researcher in immunology, ImmunoPharmaceuticals specifically focuses on immunologically active drugs recently tested for clinical activity or recently approved for medical use. Each chapter focuses on a single drug or class of drugs and discusses data from basic and preclinical research concerning mechanisms of action. Preclinical models are compared with clinical findings to allow the reader to evaluate the predictive value of those models. Featured drugs are being studied for therapy of cancer, arthritic disease, autoimmune disease, immunodeficiency disease, transplantation, and determination of sepsis. Overviews of the retinoids in cancer therapy and preclinical studies on flavonoids are featured.
FK-506: Pre-Clinical and Clinical Studies, W.H. Parsons and N.H. Sigal
Rapamycin (Sirolimus, Rapamune ™): A Novel Immunosuppressive Agent, K.L. Molnar-Kimber and S. N. Sehgal
Deoxyspergualin for Immune Suppression, M.A. Tepper and S.L. Kelley
Retinoids in Cancer, R. Warrell
Bestatin for Anti-Cancer Treatments, J.E. Talmadge, K. Ino, and P.J. Bierman
Synthetic Guanine Ribonucleosides as Immunostimulants, B.L. Pope and M.G. Goodman
Radioimmunopharmaceuticals for Immunodiagnostic Imaging, H.F. Solomon
The Flavonoids as Potential Therapeutic Targets, E. Middleton, Jr.